Lastly, experimental cancer therapeutics are exploring synthetic molecules mimicking IGFBP’s IGF-1 binding properties, though their effectiveness is limited by IGF-1 independent and sometimes tumor-promoting actions of IGFBPs [147,148]. The gene discussed is IGF1; the disease is cancer.